Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
about
KASL clinical practice guidelines: management of hepatitis CINF- α and ototoxicity.Effect of interferon treatment on hearing of patients with chronic hepatitis C.Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects.Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment.Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapyAcute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection.Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future.Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case reportSudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment.Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin.KASL clinical practice guidelines: management of hepatitis C.Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir.
P2860
Q26752471-A27A61FE-2578-491B-A4F0-BC4ED08E058DQ30450272-2DE79AC8-E918-4181-A869-5FE15E7BFF0DQ30475450-BE366595-3791-4DC3-9C57-12E9300CEA5CQ34164776-F0C40E52-F1D6-4479-9EF2-7060FF1AE595Q35222364-FA5E4C18-62A7-4908-9861-C940C85D1BAAQ36214023-CEB002EE-A363-42E7-BE54-CCE574D9F1B0Q37174206-05F49B3A-A7C9-4E2C-9733-EB012B6A53A0Q37846232-2A0A8394-8CC8-4AD4-A75C-4CB90A212091Q39219670-375CCBAA-6FE6-4925-A515-53ABF7A7A221Q42909683-8A801BAD-B9A9-4BC7-BC2D-DE9845794C9DQ50430531-A736CB66-47BA-4EF8-99F6-B6CD92A61AFBQ50432748-A8584E86-C0B9-4A0C-859F-D1B4CC101363Q50456295-B3F7CE87-CC47-486F-BC63-B2DD4927DAB9Q51836024-883E6185-4FEC-44E9-AEF0-807DF3FF4E03Q55405964-5193158C-750F-414F-9A35-67E57CD9CAF8
P2860
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Sudden hearing loss in patient ...... egylated interferon/ribavirin.
@en
Sudden hearing loss in patient ...... egylated interferon/ribavirin.
@nl
type
label
Sudden hearing loss in patient ...... egylated interferon/ribavirin.
@en
Sudden hearing loss in patient ...... egylated interferon/ribavirin.
@nl
prefLabel
Sudden hearing loss in patient ...... egylated interferon/ribavirin.
@en
Sudden hearing loss in patient ...... egylated interferon/ribavirin.
@nl
P2093
P2860
P1476
Sudden hearing loss in patient ...... egylated interferon/ribavirin.
@en
P2093
Alfred Gangl
Doris-Maria Denk
Elisabeth Formann
Peter Ferenci
Petra Munda-Steindl
Rudolf Stauber
Wolfgang Jessner
P2860
P304
P356
10.1111/J.1572-0241.2004.30372.X
P407
P577
2004-05-01T00:00:00Z